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SEVERITY IN COVID-19 PATIENTS
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SUMMARY – Coronavirus was first detected in three severe pneumonia cases in Wuhan, China, 
in December 2019. Studies on red cell distribution width (RDW-CV) and mean platelet volume 
(MPV) laboratory parameters, which can be examined in complete blood count in COVID-19 pa-
tients, are still very limited. However, to the best of our knowledge, there are no studies examining the 
relationship between platelet volume index (PVI) and disease severity in COVID-19 patients, which 
was evaluated in this study. The aim of this study was to evaluate the relationship of disease severity in 
COVID-19 patients with their MPV, RDW, and PVI parameters. The study included 92 COVID-19 
patients as a study group and 84 healthy individuals as control group. All laboratory data and radio-
logical images were scanned retrospectively from patient files and hospital information system. Evalu-
ation of the RDW-CV and MPV blood parameters, and PVI measured in COVID-19 patients yield-
ed statistically significant differences according to the disease severity. We suggest that RDW-CV and 
PVI, evaluated within the scope of the study, may be the parameters that should be considered in the 
early diagnosis of the disease, from the initial stages of COVID-19. In addition, we think that the 
RDW-CV and MPV laboratory parameters, as well as PVI, which all are simple, inexpensive and 
widely used hematologic tests, can be used as important biomarkers in determining COVID-19 se-
verity and mortality.
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Introduction
Coronavirus was first detected in three severe 
pneumonia cases in Wuhan, China, in December 
2019. Besides its flu-like symptoms, the severe acute 
respiratory syndrome coronavirus 2  (SARS-CoV-2) 
causes multiorgan failure and death with its rapid pro-
gression. This very contagious disease was accepted as 
a worldwide pandemic by the World Health Organi-
zation as of February 20201,2. Coronavirus (COV-
ID-19), which was first thought to be transmitted 
from bat, belongs to the betacoronavirus family, which 
is a subtype of the SARS group viruses. To exert its 
effect, coronavirus binds to the angiotensin-converting 
enzyme-2 receptor on the cell surface3.
Pneumonia in COVID-19 patients is thought to 
be associated with neutrophil infiltration in the lungs 
and increased serum proinflammatory cytokines and 
chemokines, together with a high onset viral load4. 
Some studies have reported changes in hematologic 
parameters during acute infection caused by SARS-
CoV-25-11.
Red cell distribution width (RDW), mean platelet 
volume (MPV), and platelets are some of the hemato-
logic parameters. RDW is a routinely reported marker 
of complete blood count (CBC) and represents a mea-
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sure of red blood cell size heterogeneity12. The RDW 
laboratory parameter has been associated with many 
diseases such as social pneumonia, hypoxemia, and 
pulmonary embolism13-15.
Platelets are one of the hematologic parameters as 
essential cells for host defense and repair, in addition 
to being known as the main effectors of hemostasis16. 
Platelets contribute to a variety of immune responses 
and a range of inflammatory disorders in the lungs and 
other organs17,18. Studies have reported that platelet 
count is a biomarker which is independently associat-
ed with disease severity and mortality risk in critically 
ill patients in intensive care unit (ICU)19-21. Recent 
studies have reported that platelet parameters may 
contribute to the diagnosis of diseases and have a 
prognostic value in some pathologies22. The MPV lab-
oratory parameter is a promising marker that may in-
dicate systemic inflammation23,24. The literature em-
phasizes that the MPV blood parameter can be useful 
in the diagnosis of inflammatory diseases such as 
pneumonia, as well as in the prognosis evaluation in 
chronic diseases such as tumors, diabetes, and coronary 
heart disease25-27.
Since the COVID-19 pandemic is a recent situa-
tion, treatment and vaccination studies are still ongo-
ing. Treatment methods are changing every day due to 
the development of new unknown symptoms and or-
gan failure, and the literature is renewed in the light of 
new studies. Preventing progression of the disease 
with early diagnosis and effective treatment strategies 
of COVID-19, and reducing mortality is one of the 
main goals. Studies on RDW-CV and MPV labora-
tory parameters, which can be examined in CBC in 
COVID-19 patients, are still very limited. Platelet vol-
ume index (PVI; MPV/platelet ratio) can contribute 
to clarifying the activities of platelets that are involved 
in inflammation28.
In some previous studies, it has been reported that 
PVI is one of the thromboembolism markers, and may 
be an important marker in evaluating the risk of car-
diovascular disease in diabetes and hypertension29,30. 
However, to the best of our knowledge, there are no 
studies examining the relationship between PVI and 
disease severity in COVID-19 patients, and it was in-
vestigated in the present study.
In this study, we aimed to evaluate the relationship 
of disease severity in COVID-19 patients with their 
MPV, RDW and PVI parameters.
Subjects and Methods
Study participants
The study was conducted between March 15, 2020 
and June 20, 2020 as a retrospective single-center study. 
The study included 92 COVID-19 patients as a patient 
group and 84 healthy individuals as control group. The 
study was approved by the Ethics Committee of the 
Yozgat Bozok University as of July 22, 2020, decision 
no. 2020-06-147. The study was carried out in accor-
dance with the Helsinki Declaration. The patient group 
consisted of COVID-19 patients admitted to the 
Emergency Department with various symptoms and 
complaints, whose diagnosis was confirmed by real-
time reverse transcription-polymerase chain reaction 
(rRT-PCR). The healthy control group consisted of 
people who presented to the hospital for general ex-
amination. COVID-19 patients were subdivided ac-
cording to the diagnostic criteria of the COVID-19 
(2019-nCoV Disease) Guide published by the Turkish 
Ministry of Health and updated with recent develop-
ments31. Accordingly, patient groups were defined as 
group 1 with mild severity, group 2 with medium sever-
ity, group 3 with high severity, and group 4 as critical 
cases. Group 1 patients had mild clinical symptoms 
and group 2 patients had fever, respiratory symptoms 
and radiological findings of pneumonia. Patients with 
any of the symptoms of shortness of breath, respiratory 
rate (RR) ≥30/min, oxygen saturation value ≤93% at 
rest, and (PaO2/FiO2) ≤300 mm Hg were included in 
group 3. Patients with respiratory failure requiring me-
chanical ventilation, clinical picture of shock or organ 
failure were included in group 4. In order to facilitate 
the clinicians’ planning of COVID-19 patient follow 
up, in addition to the patient group diagnostic guide, it 
was also planned to evaluate COVID-19 patients in 
two groups where one group included patients with se-
rious to critical severity and the other group included 
patients with mild to moderate severity.
Data collection
Patients included in the study were analyzed for 
age, gender, hospital admission symptoms, chronic dis-
ease history, clinical outcomes, survival, and CBC pa-
rameters determined on a Sysmex XN-1000 hemato-
logic analyzer (Sysmex Co., Japan). Patient serum bio-
chemistry was performed on a Roche Cobas C501 
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chemistry analyzer (Roche Diagnostics, Mann heim, 
Germany). All laboratory data and radiological images 
were scanned retrospectively from patient files and 
hospital information system. Data on patient clinical 
outcomes and survival were obtained from the hospital 
information system. PVI was calculated as PVI=MPV 
value (fl)/Plt per 1000 x10032, and then recorded.
Statistical analysis
All data were statistically analyzed with the SPSS 
version 20.0 for Windows. Kolmogorov-Smirnov test 
and skewness-kurtosis method were used to evaluate 
normal distribution of all variables. Additionally, nor-
mal data distribution was evaluated by a histogram. 
The χ2-test and Fisher exact test were used to compare 
proportions of categorical variables. Descriptive statis-
tics was used to analyze patient demographic data. 
Numerical values were expressed as mean ± standard 
deviation and minimum-maximum values. Student’s 
t-test was used for parametric variables within the 
scope of clinical research. Kruskal-Wallis H test and 
Mann-Whitney U test were used for statistical evalu-
ation of non-parametric variables depending on their 
categorical (nominal or ordinal) and numerical inde-
pendence status. Spearman rank correlation method 
was used for correlation of nonparametric data. Ac-
cording to clinical results of COVID-19 patients, 
RDW-CV, MPV and PVI values were evaluated with 
the receiver-operating characteristic curve (ROC). On 
ROC analysis, parameters with the area under the 
curve (AUC) value below 0.6 and without statistical 
significance (p>0.05) were excluded. The level of sta-
tistical significance was set at p<0.05.
Results
Between March 15, 2020 and June 20, 2020, 230 
patients were admitted to the Emergency Department 
due to upper and lower respiratory tract infections. Of 
these, 92 patients had positive PCR test result, where-
as 128 patients were diagnosed with other upper and 
lower respiratory tract infections and were excluded 
from the study. In our study, data on 92 patients admit-
ted to the hospital with confirmed COVID-19 diag-
nosis were analyzed (Table 1). There was no significant 
difference in median age between 92 confirmed CO-
VID-19 patients and 84 controls (p>0.05). In the pa-
tient group, there were 47 (51.1%) male and 45 (48.9%) 
female patients. In the control group, there were 43 
male and 41 female subjects, yielding no significant 
between-group difference in gender composition 
(p>0.05).
Demographic and clinical characteristics  
of COVID-19 patients and healthy control group
Demographic characteristics and clinical findings 
of the 92 COVID-19 patients and 84 healthy control 
subjects are summarized in Table 1. Median age of 
COVID-19 patients and control subjects was 61.3 and 
58.5 years, with no significant difference between the 
groups (p<0.05). Although median age of the COV-
ID-19 patient groups was higher in critically ill pa-
tients, there was no statistically significant difference 
between the groups (p>0.05). Similarly, even though 
there was no statistically significant difference in gen-
der distribution by clinical groups in the COVID-19 
patient group, the proportion of male patients was 
higher than of female patients, especially in severe 
COVID-19 cases. Fever, dyspnea and cough were the 
most common clinical symptoms in study patients, as 
well as in COVID-19 patients with moderate disease 
severity. There was a statistically significant difference 
in the symptoms of dyspnea and joint pain (p<0.05) 
between the groups. Comorbidities were recorded in 
54.9% (n=51) of COVID-19 patients. Table 1 shows 
comorbidity distribution in the patient and control 
groups. Accordingly, disease severity in patients with 
chronic obstructive pulmonary disease (COPD) and 
coronary artery disease comorbidities was higher in 
the severe and critical groups, and this difference was 
significantly higher as compared with other patient 
groups (mild and moderate) (p<0.05).
Laboratory characteristics of COVID-19 patients  
and healthy control group
Differences in laboratory findings between 
 COVID-19 patients and control group are shown in 
Table 2. Patient group had higher leukocyte levels 
(p<0.05) and lower total protein levels (p<0.05) than 
control group. Besides, hypoalbuminemia (serum al-
bumin ≤40 g/L) and lymphopenia (lymphocyte count 
≤1.1x109/L) were observed in the COVID-19 patient 
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group (p<0.05). L-lactate dehydrogenase (LDH) val-
ues were significantly higher than in healthy controls 
(p<0.05); however, RDW-CV levels and PVI were sig-
nificantly higher in the COVID-19 patient group 
compared to healthy controls (p<0.05). Ferritin, C-re-
active protein (CRP) and sedimentation acute phase 
reactants were significantly higher compared to the 
healthy control group (p<0.05). As shown in Table 2, 
difference in MPV values was not statistically signifi-
cant (p=0.387).
Laboratory parameters according to disease severity  
in COVID-19 patients
Laboratory parameters of COVID-19 patients di-
vided into 4 groups were compared to investigate the 
effect of disease severity on blood parameters. Differ-
ences in laboratory findings among groups are shown 
in Table 3. Analysis of the RDW-CV and MPV blood 
parameters, and PVI (in this study investigated in 
COVID-19 patients) yielded statistically significant 
difference according to disease severity (p<0.05). 
However, difference in the platelet laboratory param-






























Age (yrs)  
(min-max) 58.5 (22-82) 61.3 (23-94) 0.205 57 (28-73) 60.5 (41-82) 61 (23-94) 70.5 (35-81) 0.201
Gender 0.531 0.271
Male, n (%) 51 (55.4%) 44 (52.3%) 8 (47.1%) 24 (53.3%) 12 (75%) 5 (41.7%)
Female, n (%) 41 (44.6%) 40 (47.6%) 9 (52.9%) 21 (46.7%) 4 (25%) 7 (58.3%)
Comorbidity 41 (45.1%) 51 (54.3%) 0.264 10 (58.8%) 22 (48.9%) 7 (43.8%) 10 (83.3%) 0.141
Hypertension 25 (28.4%) 33 (36.7%) 6 (35.3%) 14 (31.1%) 7 (43.8%) 6 (50%) 0.598
Diabetes 18 (20.4%) 22 (24.4%) 4 (23.5%) 8(17.8%) 5 (31.3%) 5 (41.7%) 0.331
COPD 9 (10.2%) 12 (13.3%) 1 (5.9%) 2 (6.7%) 3 (12.5%) 6 (50%) 0.001*
CAD 9 (10.7%) 11 (12.2%) 0 4 (8.9%) 4 (25%) 3 (25%) 0.039*
Cerebrovascular 
disease 1 (1.1%) 1 (1.1%) - 1 (2.2%) 0 0 0.780
Chronic kidney 
disease 5 (5.6%) 4 (4.4%) 1 (5.9%) 3 (6.7%) 0 0 0.592
Viral hepatitis - 1 (1.1%) 0 0 0 1 (8.3%) 0.056
Asthma 6 (6.8%) 4 (4.4%) 0 2 (4.4%) 1 (6.3%) 1 (8.3%) 0.858
Symptom-sign
Fever - 47 (51.6%) 7 (14.9%) 24 (51.1%) 9 (19.1%) 7 (14.9%) 0.665
Dyspnea - 46 (50.5%) 6 (13%) 20 (43.5%) 11 (23.9%) 9 (19.6%) 0.045*
Cough - 42 (46.2%) 6 (14.3%) 23 (54. %8) 6 (14.3%) 7 (16.7%) 0.418
Weakness - 27 (29.7%) 8 (29.6%) 14(51.9%) 2 (7.4%) 3(11.1%) 0.230
Sore throat - 9 (9.9%) 4 (44.4%) 2 (22.2%) 2 (22.2%) 1 (11.1%) 0.226
Anosmia - 5 (5.5%) 1 (20%) 2 (40%) - 2 (40%) 0.271
Diarrhea - 11 (12.1%) 2 (18.2%) 4 (36.4%) 2 (18.2%) 3 (27.3%) 0.506
Chest pain - 5 (5.5%) 3 (60%) 1 (20%) 1 (20%) 0.372
Headache - 4 (4.4%) 1 (25%) 1 (25%) 2 (50%) - 0.306
Joint pain - 17 (18.7%) 8 (47.1%) 7 (41.2%) - 2 (11.8%) 0.008*
*p<0.05 was considered statistically significant; COPD = chronic obstructive pulmonary disease; CAD = coronary artery disease
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eter among the disease severity groups was not statisti-
cally significant (p>0.05). Correlation between disease 
severity and laboratory parameters is shown in Table 4. 
Accordingly, RDW-CV, MPV and PVI values were 
found to have a moderately positive correlation with 
disease severity. Evaluation of the patient survival rate 
showed that 78% (n=71) of the patients survived and 
22% (n=20) deceased. Analysis of lung images of CO-
VID-19 patients showed involvement of the right up-
per lobe in 63.2% (n=53), right middle lobe in 65.5% 
Table 2. Results of laboratory parameters in COVID-19 patients and control group
Laboratory parameter Control group  (mean ± SD)
COVID-19 patient group  
(mean ± SD) p value
Red blood cell distribution width‐CV (RDW-CV)(%) 12.8±0.7 13.6±1.3 0.000*
Mean platelet volume (MPV), fl 10.3±0.94 10.1±1.06 0.387
PVI (MPV/platelet ratio) 3.2±1.2 5.7±2.5 0.000*
Total protein (65‐85 g/L) 73.2±4.5 69.8±7.8 0.048
Albumin (40‐55 g/L) 46.13±2.5 39.8±4.8 0.000*
LDH, U/L 172.5±26 247.6±55.2 0.000*
Ferritin, mL/ng 364.5±54.4 58.4±49.9 0.003*
C‐reactive protein (0-6 mg/L) 1.5±0.9 53.12±10.4 0.010*
Hemoglobin, g/L 14.2±1.2 13.8±1.8 0.276
Platelet x109/L 293±55.2 209.4±58.3 0.000*
WBC (4.0‐10.0×109/L) 7.2±1.3 10.04±3.8 0.023*
Neutrophil (2.0‐6.0×109/L) 4.1±1.23 5.7±3.5 0.013*
Lymphocyte (1.1‐3.2×109/L) 2.3±0.7 1.6±0.9 0.000*
SD = standard deviation; PVI = platelet volume index; LDH = L-lactate dehydrogenase; WBC = white blood count; Mann-Whitney U test 
was used on statistical analysis; *p<0.05 was considered significant





















Red blood cell distribution width‐CV (%) 13.2±1.9 13.5±0.8 13.6±1.19 14.4±1.16 0.000*
Mean platelet volume, fl 9.9±0.8 10.1±1.08 10.2±1.08 10.4±1.2 0.044*
PVI 5.01±1.8 5.4±2.04 5.8±2.02 7.8±4.4 0.000*
Total protein (65‐85 g/L) 73±3.3 72.4±5.5 68.8±4.21 67.7±4.8 0.048*
Albumin (40‐55 g/L) 40.8±3.3 40.2±4.2 40.1±4.1 36.2±3.8 0.000*
LDH, U/L 230.4±70 240.7±65 264.8±75 270.4±85 0.000*
C‐reactive protein(0-6 mg/L) 26.8±4.2 43.7±7.2 57.7±6.8 102.5±20.7 0.010*
Platelet x109/L 219.7±104 203±52.6 201.6±80 200±68 0.704
WBC (4.0‐10.0 × 109/L) 7.6±3.1 7.8±4 8±3.5 9.6±3.8 0.023*
Neutrophil (2.0‐6.0×109/L) 4.1±1.23 5.7±3.5 6.1±3.3 6.8±3.9 0.013*
Lymphocyte
(1.1‐3.2×109/L) 1.9±0.8 1.6±0.9 1.5±0.6 1.19±0.8 0.000*
SD = standard deviation; LDH = L-lactate dehydrogenase; WBC = white blood count; PVI = platelet volume index; Kruskal-Wallis H test 
was used on statistical analysis; *p<0.05 was considered significant
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the AUC, cut-off, sensitivity, and specificity of 
RDW-CV and MPV laboratory parameters, and 
MPV/Plt ratio were analyzed with ROC curve to 
guide the clinician concerning diagnostic efficacy and 
follow-up of COVID-19 patients. However, mortality 
rates, cut-off points, sensitivity and specificity of these 
laboratory parameters were also analyzed with ROC 
curve in COVID-19 patients. The cut-off values, 
AUC, sensitivity and specificity of RDW-CV, MPV 
and MPV/Plt parameters, which were found to be sta-
tistically significant, were determined to be used in 
distinguishing the clinical pictures of COVID-19 
cases and in their follow-up in critical care units. For 
the RDW-CV parameter, the AUC, cut-off, sensitivity 
and specificity were 0.734%, 13.65%, 95% and 66%, 
respectively. The AUC, cut-off, sensitivity, specificity of 
the MPV/Plt ratio were 0.745, 0.057, 80% and 65%, 
respectively. The AUC, cut-off, sensitivity and specific-
ity of the MPV parameter were 0.714%, 11.05, 55% 
and 81%, respectively (Table 6, Fig. 1).
The AUC, cut-off, sensitivity and specificity for the 
RDW-CV parameter in predicting mortality were 
0.800%, 13.75%, 89.3% and 71%, respectively. The 
AUC, cut-off, sensitivity and specificity of the MPV/Plt 










Spearman rank correlation method was used on statistical analysis; 
*p<0.05 was considered significant; RDW-CV = red blood cell dis-
tribution width; MPV = mean platelet volume; PVI = platelet vol-
ume index
Table 5. Laboratory parameters according to clinical groups of COVID-19 patients
Laboratory parameter Mild-moderate COVID-19 group (mean ± SD)
Severe-critical COVID-19 
group (mean ± SD) p value
Red blood cell distribution width‐CV (%) 13.2±1.9 13.6±1.19 0.000*
Mean platelet volume, fl 9.9±0.8 10.2±1.08 0.043*
PVI 5.3±1.9 6.7±2.3 0.000*
C‐reactive protein (0-6 mg/L) 26.8±4.2 57.7±6.8 0.010*
Platelet x109/L 219.7±104 201.6±80 0.000*
WBC (4.0‐10.0 × 109/L) 7.8±3.8 8.79±3.7 0.023*
Neutrophil (2.0‐6.0×109/L) 5.5±3.4 6.4±3.6 0.013*
Lymphocyte (1.1‐3.2×109/L) 1.6±0.7 1.5±0.7 0.000*
SD = standard deviation; WBC = white blood count; PVI = platelet volume index; Mann-Whitney U test was used on statistical analysis; 
*p<0.05 was considered significant
Table 6. ROC analysıs of laboratory parameters for use in COVID-19 severity monitoring plan
Laboratory 
parameter Cut-off value AUC p value
95% CI  
(lower bound- upper bound) Sensitivity % Specificity %
RDW-CV, % 13.65 0.734 0.001 0.634-0.834 95 66
MPV, fl 11.05 0.711 0.004 0.538-0.840 55 81
PVI 0.057 0.745 0.001 0.627-0.864 80 65
ROC = receiver operating characteristic curve; AUC = area under curve; 95% CI = 95% confidence interval; RDW = red cell distribution 
width; MPV = mean platelet volume; PVI = platelet volume index
(n=57), right lower lobe in 77.9% (n=67), left upper 
lobe in 64% (n=54) and left lower lobe in 86% (n=74) 
of the patients.
ROC analysis for RDW-CV, MPV  
and MPV/Plt parameters
Laboratory parameters of the COVID-19 patients 
divided into mild-moderate and severe-critical severi-
ty groups according to their clinical findings are shown 
in Table 5. By dividing COVID-19 patients into two 
groups of mild-moderate and severe-critical severity, 
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ratio were 0.650, 0.057, 68% and 63%, respectively. Al-
though it was found to be statistically significant in pre-
dicting mortality, as shown in Table 7, the specificity 
Fig. 1. ROC analysis of laboratory parameters according 
to clinical groups of COVID-19 patients.
MPV = mean platelet volume; RDW = red blood cell distribution 
width; PVI = platelet volume index
Table 7. ROC analysis of laboratory parameters to predict mortality
Laboratory 
parameter Cut-off value AUC p value
95% CI  
(lower bound- upper bound) Sensitivity % Specificity %
RDW-CV % 13.75 0.800 0.000 0.634-0.834 89.3 71
MPV, fl 10.1 0.630 0.049 0.538-0.840 53 61
PVI 0.057 0.745 0.023 0.627-0.864 68 63
ROC = receiver operating characteristic curve; AUC = area under curve; 95% CI = 95% confidence interval; RDW = red cell distribution 
width; MPV = mean platelet volume; PVI = platelet volume index
Fig. 2. Laboratory parameters for predicting mortality by 
ROC analysis.
MPV = mean platelet volume; RDW = red blood cell distribution 
width; PVI = platelet volume index
and sensitivity of the MPV parameter were found to be 
lower than RDW-CV and MPV/Plt ratio (Fig. 2).
Discussion
COVID-19 is an acute infectious disease caused by 
a new coronavirus (SARS-CoV-2) and can progress 
from mild symptoms such as fever, dry cough, joint 
pain, and sore throat to a severe picture such as short-
ness of breath, respiratory failure and multiple organ 
dysfunction syndrome33. However, there also are as-
ymptomatic patients presenting no symptoms. With 
increase in the number of asymptomatic COVID-19 
patients, the potential risk of contagion increases34. 
Early diagnosis of the disease and active and effective 
treatment plans anticipating and containing exacerba-
tion of the disease can reduce mortality. In the light of 
constantly updated information on COVID-19, easy-
to-use, low-cost and widely used laboratory tests are 
important in determining the severity of the disease. 
Comparison of hematologic parameters in our study 
revealed that COVID-19 patient group had signifi-
cantly higher white blood cell (WBC), neutrophil, 
LDH, ferritin and CRP values compared to the 
healthy control group (p<0.05). However, lympho-
cytes, platelets, total protein and albumin were signifi-
cantly lower in COVID-19 patients (p<0.05). These 
data are consistent with those reported in the litera-
ture35-38. However, many studies report that lymphope-
nia is caused by depletion of lymphocytes by the im-
mune system organs after lymphocyte invasion of 
SARS‐CoV‐235,36,39,40.
Evaluation of the RDW-CV laboratory parameter, 
which was investigated in this study, showed that this 
parameter was significantly higher in COVID-19 pa-
tients as compared with control group. It was also on 
rise in the critical patient group, and this difference 
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was significantly higher among patient groups. Fur-
thermore, our study found that this parameter was sig-
nificantly higher in COVID-19 patients in terms of 
predicting mortality. Regarding the RDW-CV param-
eter, when damage to the immune system and suppres-
sion of the bone marrow occurs in the human body, 
compensatory hyperplasia of the erythroid cell line is 
activated. However, a large number of immature red 
blood cells are released, which in turn increases the 
RDW. The RDW-CV laboratory parameter is in-
creased in cases that develop multiorgan failure such as 
severe sepsis41. Similarly, in COVID-19, an increase in 
the RDW-CV laboratory parameter is common due to 
damage to the immune system. However, Kim et al. 
report that the RDW parameter was a predictor of 
mortality during multiorgan failures such as sepsis and 
septic shock41. Considering that COVID-19 may also 
progress to multiorgan failure, the RDW-CV results 
in our study support those literature reports. Accord-
ingly, we suggest that the RDW-CV parameter may be 
a predictor of mortality in COVID-19 patients. In 
their study on COPD patients, Kalemci et al. found 
that the RDW laboratory parameter increased signifi-
cantly with the disease severity and development of 
hypoxemia42. The fact that COVID-19 severely affects 
the lungs and causes hypoxemia in the advanced stages 
of the disease supports the RDW-CV results in our 
study.
Platelets are important immune cells that play a 
role in hemostasis and coagulation, as well as in the 
immune and inflammatory mechanisms43. Differences 
in platelet count and activity are associated with vari-
ous diseases44,45; in acute respiratory failure, platelets 
tend to decrease as a result of damage to the lungs46. In 
a study conducted in atypical pneumonia patients, 
platelets were also decreased47. In our study, platelet 
levels were found to be significantly lower in COV-
ID-19 patients compared to healthy controls. Consid-
ering that SARS‐CoV‐2 causes damage to the lungs, 
our findings are similar to the low platelet levels re-
ported in the literature. However, another result of this 
study was that the platelet laboratory parameter did 
not help us evaluate the severity of the disease. Simi-
larly, Wang et al. in their COVID-19 study report that 
platelet levels were not effective in evaluating the se-
verity of the disease48, which is similar to the findings 
in our study.
Evaluation of the MPV laboratory parameter, also 
investigated in this study, showed that there was no 
difference in MPV values between the healthy control 
group and COVID-19 patients. Korniluk et al. report 
that MPV acted as an acute phase reactant in different 
inflammatory conditions49. The increase in the MPV 
parameter during the inflammatory state is probably 
associated with increase in the percentage of large 
platelets due to the intracellular synthesis of pro-coag-
ulatory and pro-inflammatory factors, and degranula-
tion of granules50. It has been reported that a change in 
the MPV laboratory parameter is observed in sepsis 
and systemic inflammatory response syndrome com-
pared to healthy population51-53. This difference be-
tween our study and previous studies has emerged be-
cause the selected patient population had a more se-
vere clinical course in those studies. Moreover, in our 
study, difference was found between the groups on 
evaluating the severity of the MPV parameter, and 
there was an increasing trend towards the severe pa-
tient group. In our study, the fact that the MPV values 
in severe COVID-19 patients were significant com-
pared to other COVID-19 groups can be useful in 
predicting disease severity. Two studies in the litera-
ture emphasize that the MPV parameter is a biomark-
er indicating poor prognosis54,55. In our study, the sig-
nificance of the MPV laboratory parameter in the 
evaluation of mortality may be useful for clinicians in 
evaluating prognosis. In a study conducted in diabetic 
COVID-19 patients, it is reported that the MPV val-
ue was increased in these patients23. In our study, a sig-
nificant increase was found in the MPV values of CO-
VID-19 patients with comorbidities such as diabetes. 
If COVID-19 patients have comorbidities in their 
history, the MPV laboratory parameter may also be 
beneficial for clinicians in patient observation.
Since COVID-19 is a disease with multiple vari-
ables, many studies are still ongoing. In this study, the 
MPV/Plt ratio was found to be significantly higher in 
COVID-19 patients compared to healthy population. 
The importance of PVI in evaluating platelet activa-
tion and predicting mortality has been reported in pre-
vious studies53,56. Similar to our study, Ates et al. found 
that the MPV/Plt ratio was significantly higher in 
sepsis patients compared to control group53. Fei et al. 
state that PVI could be beneficial in the diagnosis and 
differential diagnosis of disease in their study of the 
influenza virus57. This study also found that PVI was 
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useful in evaluating disease severity and predicting 
mortality, as well as diagnosing COVID-19.
To facilitate the clinicians’ planning follow up of 
COVID-19 patients, this study evaluated COVID-19 
patients divided into two groups, i.e. a group of pa-
tients with serious to critical severity COVID-19 and 
group of patients with mild to moderate severity CO-
VID-19. In addition to the patient group diagnostic 
guide, the RDW-CV, MPV and MPV/Plt ratio were 
found to be significantly higher in the serious-critical 
severity group as compared to the mild-moderate se-
verity group; moreover, when the relationship between 
the groups was evaluated, moderate correlation was 
found with these laboratory parameter values. The 
high sensitivity of RDW-CV and PVI may help clini-
cians in the assessment of the patient clinical course 
from the first follow up.
This study had some limitations, including a rela-
tively small sample size and single-center design.
Conclusion
In conclusion, we think that the RDW-CV labora-
tory parameter and PVI, which were evaluated within 
the scope of the study, may be the parameters that 
should be considered in the early diagnosis of the dis-
ease from the initial stages of COVID-19. In addition, 
we think that the RDW-CV and MPV laboratory pa-
rameters, and PVI, which are among the simple, inex-
pensive and widely used hematologic tests, can be used 
as important biomarkers in defining the disease sever-
ity and evaluating its mortality. We believe that these 
parameters will facilitate early clinical intervention in 
COVID-19, thereby contributing to the reduction of 
patient mortality.
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Sažetak
PROCJENA ODNOSA SREDNJEG VOLUMENA TROMBOCITA,  
ŠIRINE DISTRIBUCIJE ERITROCITA I INDEKSA VOLUMENA TROMBOCITA  
S TEŽINOM BOLESTI KOD BOLESNIKA S COVID-19
D. Atik i H.B. Kaya
Koronavirus je prvi put otkriven kod tri slučaja teške upale pluća u Wuhanu, Kina u prosincu 2019. godine. Istraživanja 
laboratorijskih parametara širine distribucije eritrocita (RDW-CV) i srednjeg volumena trombocita (MPV) koji se mogu 
testirati unutar kompletne krvne slike kod bolesnika s COVID-19 još uvijek su vrlo ograničena. Međutim, prema našim 
saznanjima, nema istraživanja koja bi se bavila odnosom indeksa volumena trombocita (PVI) i težine bolesti kod ovih bo-
lesnika, a upravo to smo ispitivali u našem istraživanju. Cilj studije bio je procijeniti odnos težine bolesti u bolesnika s 
 COVID-19 s parametrima MPV, RDW i PVI. Istraživanje je obuhvatilo 92 bolesnika s COVID-19 i 84 zdrave osobe kao 
kontrolna skupina. Svi laboratorijski podaci i radiološke snimke preslikane su retrospektivno iz bolesničkih kartona i bolnič-
kog informacijskog sustava. Procjena krvnih parametara RDW-CV i MPV, kao i PVI izmjerenih u bolesnika s COVID-19 
pokazala je statistički značajne razlike prema težini bolesti. Predlažemo da bi RDW-CV i PVI koji su istraživani u ovoj 
studiji mogli poslužiti kao parametri u ranoj dijagnostici bolesti već u početnom stadiju COVID-19. Uz to, smatramo da bi 
se laboratorijski parametri RDW-CV i MPV te PVI kao jednostavne, jeftine i široko primjenjivane hematološke pretrage 
mogli primijeniti kao važni biološki biljezi u utvrđivanju težine i smrtnosti COVID-19.
Ključne riječi: COVID-19; Težina bolesti; Srednji volumen trombocita; Širina distribucije eritrocita; Indeks volumena trom-
bocita
